Medulloblastoma is the most common form of pediatric brain cancer with a five-year survival rate of approximately 70%, yet for some children’s survival is as low as 40%. Many of the treatment options for these patients may be effective in extending the five-year survival rate, however, quality of life issues still persist for these young patients including learning and developmental deficits. These side effects arise from damage to normal tissue in the developing brain by surgery and/or drug and radiation therapy.